Literature DB >> 31263028

Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.

Jason A Willis1, Michael J Overman2, Eduardo Vilar3,4,5.   

Abstract

New approaches are required for addressing the important and unmet need to expand the benefits of checkpoint blockade to patients with mismatch repair proficient colorectal cancer. Systematic profiling of the tumor immune microenvironment provides insights into potential mechanisms of resistance, predictive biomarkers, and novel combinatorial strategies for overcoming resistance.See related article by Llosa et al., p. 5250. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2019        PMID： 31263028      PMCID： PMC6726523          DOI： 10.1158/1078-0432.CCR-19-1447

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.

Authors:  Nicolas J Llosa; Brandon Luber; Ada J Tam; Kellie N Smith; Nicholas Siegel; Anas H Awan; Hongni Fan; Teniola Oke; JiaJia Zhang; Jada Domingue; Elizabeth L Engle; Charles A Roberts; Bjarne R Bartlett; Laveet K Aulakh; Elizabeth D Thompson; Janis M Taube; Jennifer N Durham; Cynthia L Sears; Dung T Le; Luis A Diaz; Drew M Pardoll; Hao Wang; Robert A Anders; Franck Housseau
Journal:  Clin Cancer Res       Date:  2019-05-06       Impact factor: 12.531

Review 2.  Roles for Interleukin 17 and Adaptive Immunity in Pathogenesis of Colorectal Cancer.

Authors:  Christopher G Hurtado; Fengyi Wan; Franck Housseau; Cynthia L Sears
Journal:  Gastroenterology       Date:  2018-09-13       Impact factor: 22.682

Review 3.  Immunotherapy in colorectal cancer: rationale, challenges and potential.

Authors:  Karuna Ganesh; Zsofia K Stadler; Andrea Cercek; Robin B Mendelsohn; Jinru Shia; Neil H Segal; Luis A Diaz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06       Impact factor: 46.802

4.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

Authors:  Daniel Sanghoon Shin; Jesse M Zaretsky; Helena Escuin-Ordinas; Angel Garcia-Diaz; Siwen Hu-Lieskovan; Anusha Kalbasi; Catherine S Grasso; Willy Hugo; Salemiz Sandoval; Davis Y Torrejon; Nicolaos Palaskas; Gabriel Abril Rodriguez; Giulia Parisi; Ariel Azhdam; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Beata Berent-Maoz; I Peter Shintaku; Dung T Le; Drew M Pardoll; Luis A Diaz; Paul C Tumeh; Thomas G Graeber; Roger S Lo; Begoña Comin-Anduix; Antoni Ribas
Journal:  Cancer Discov       Date:  2016-11-30       Impact factor: 39.397

Review 5.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Authors:  Jérôme Galon; Daniela Bruni
Journal:  Nat Rev Drug Discov       Date:  2019-03       Impact factor: 84.694

6.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

7.  Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Authors:  Cathy Eng; Tae Won Kim; Johanna Bendell; Guillem Argilés; Niall C Tebbutt; Maria Di Bartolomeo; Alfredo Falcone; Marwan Fakih; Mark Kozloff; Neil H Segal; Alberto Sobrero; Yibing Yan; Ilsung Chang; Anne Uyei; Louise Roberts; Fortunato Ciardiello
Journal:  Lancet Oncol       Date:  2019-04-16       Impact factor: 41.316

8.  Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

Authors:  Romain Cohen; Elisabeth Hain; Olivier Buhard; Agathe Guilloux; Armelle Bardier; Rachid Kaci; Philippe Bertheau; Florence Renaud; Frédéric Bibeau; Jean-François Fléjou; Thierry André; Magali Svrcek; Alex Duval
Journal:  JAMA Oncol       Date:  2019-04-01       Impact factor: 31.777
  8 in total
  2 in total

1.  Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.

Authors:  Chao Liu; Ruiqi Liu; Bojun Wang; Jie Lian; Yang Yao; Haoxiu Sun; Chunhui Zhang; Lin Fang; Xin Guan; Jiaqi Shi; Shuling Han; Fei Zhan; Shengnan Luo; Yuanfei Yao; Tongsen Zheng; Yanqiao Zhang
Journal:  J Immunother Cancer       Date:  2021-01       Impact factor: 13.751

2.  Sensei: how many samples to tell a change in cell type abundance?

Authors:  Shaoheng Liang; Jason Willis; Jinzhuang Dou; Vakul Mohanty; Yuefan Huang; Eduardo Vilar; Ken Chen
Journal:  BMC Bioinformatics       Date:  2022-01-04       Impact factor: 3.169
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.